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The hedgehog (HH) signaling pathway is a highly
regulated signaling pathway that is important not
only for embryonic development, tissue patterning,
and organogenesis but also for tissue repair and the
maintenance of stem cells in adult tissues. In the adult
hematopoietic system, HH signaling regulates in-
trathymic T-cell development, and it is one of the
survival signals provided by follicular dendritic cells
to prevent apoptosis in germinal center B cells. HH
signaling is required for primitive hematopoiesis;
however, conflicting data have been reported regard-
ing the role of the HH pathway in adult hematopoie-
sis. Inappropriate activation of the HH signaling path-
way occurs in several human cancers, including
hematological neoplasms. Emerging data demon-
strate abnormal HH pathway activation in chronic
lymphocytic leukemia/small lymphocytic lymphoma,
plasma cell myeloma, mantle cell lymphoma, diffuse
large B-cell lymphoma, ALK-positive anaplastic large
cell lymphoma, chronic myelogenous leukemia, and
acute leukemias. In these neoplasms, HH signaling
promotes proliferation and survival, contributes to
the maintenance of cancer stem cells, and enhances
tolerance or resistance to chemotherapeutic agents.
Here, we review current understanding of HH signal-
ing, its role in the pathobiology of hematological ma-
lignancies, and its potential as a therapeutic target to
treat malignant hematological neoplasms. (Am J
Pathol 2012, 180:2–11; DOI: 10.1016/j.ajpath.2011.09.009)
The Hedgehog Signaling Pathway
Hedgehog (HH) proteins were first identified in Drosophila
as secreted signaling proteins1 that have an essential
role in embryonic development, determining the antero-
2posterior orientation of developing structures in the Dro-
sophila embryo and larva.2 There is a single Hh gene in
Drosophila, but three homologs have been found in ver-
tebrates: sonic hedgehog (SHH), Indian hedgehog (IHH),
and desert hedgehog (DHH).3 Notably, the three HH
ligands activate the same signal transduction pathway,
but they regulate different organ systems.3–5 The SHH
gene is expressed in the central nervous system, lung,
tooth, gut, and hair follicle.6–10 IHH is involved in endo-
chondral bone formation,11 and DHH is expressed mostly
in gonads.12
HH proteins undergo a maturation process before their
active forms can be secreted from cells and activate HH
signaling. The C-terminal domain has proteolytic activity
and autocleaves the ligand molecule, generating an N-
terminal signaling peptide. This ligand peptide is modi-
fied at both ends, esterified with cholesterol moiety at the
C-terminal end, and palmitoylated with amide-linked
palmitate at the N-terminal end.13,14 The bilipidated li-
gands form multimers, which leave the ligand-producing
cell via dispatched (Disp), a 12-transmembrane protein,
and are transported via glypicans and megalin to the
major cell receptor, patched (Ptc in Drosophila; PTCH in
humans).15
The two known human homologs, PTCH1 and PTCH2,
are both composed of 12 transmembrane domains and
two extracellular loops that have HH ligand binding sites.
The PTCH1 gene is located at 9q22.1-q31 and encodes
a 1447-amino-acid glycoprotein.16 The PTCH2 gene is
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tein.17 PTCH2 and PTCH1 have different intracellular
N- and C-terminal domains.18 PTCH1 and PTCH2 are
considered to have different functions based on their
different expression during development of the epider-
mis.17 PTCH1 mutations19 are associated with nevoid
basal cell carcinoma syndrome (also known as Gorlin’s
syndrome, an autosomal dominant disorder character-
ized by multiple basal cell carcinomas and skeletal de-
fects, among other findings),20 medulloblastoma, and
meningioma; PTCH2mutations, although rare, have been
reported in medulloblastoma and basal cell carcinoma.17
In vertebrates, primary cilium is the site where activa-
tion of HH signaling occurs. A schematic representation
of HH signaling pathway activation is shown in Figure 1.
In the absence of HH ligand, PTCH inhibits the smooth-
ened protein (SMO); this protein has seven transmem-
brane domains, an extracellular N-terminus, and an intra-
cellular C-terminus, with homology to G protein-coupled
receptors (GPCRs).21,22 Binding of HH ligand to PTCH
results in endocytosis of the PTCH-ligand complex, fol-
lowed by migration of uninhibited SMO to the primary
cilium. For localization of SMO to the cilia, a short motif
C-terminal to the last transmembrane domain is re-
Figure 1. Schematic diagram of repressed (left) and activated (right) cano
primary cilium and prevents SMO from entering the cilium. This results in ph
degradation and clearance from the cell (GLI1 and GLI2) or partial proteolys
GLI3R enters into the nucleus, binds GLI binding consensus sequences, and r
DHH), PTCH is internalized, allowing migration of uninhibited SMO to the
transcription factors and transcription of HH target genes (GLI1, BCL2, PTCquired.23 -Arrestin was reported to mediate this pro-cess.24 In the cilium, uninhibited SMO transduces the
signal to the cytoplasm via intraflagellar transport pro-
teins, with glioma-associated oncogene homolog (GLI)
proteins as major targets. The GLI proteins regulate tar-
get gene expression by direct association with a consen-
sus binding site located in the promoter region of the
target genes.25 Activation of canonical HH signaling has
profound effects on the stability of GLI family of zinc-
finger transcription factors. In the absence of HH ligands,
the three isoforms of GLI transcription factors (ie, GLI1,
118 kDa; GLI2, 175 kDa; and GLI3, 174 kDa) are ubiq-
uitinated by -transducin-repeat containing protein (-
TrCP), which is a phosphorylation-dependent E3 ubiqui-
tin ligase. Ubiquitination of GLI proteins requires priming
phosphorylations by protein kinase A (PKA), casein ki-
nase 1 (CK1), and glycogen synthase kinase-3 (GSK-
3).26–28 After ubiquitination, GLI1 is completely de-
graded and cleared from the cell by the proteasomal
system, whereas GLI2 and GLI3 are partially degraded to
form low-molecular weight repressor forms (GLI2R or
GLI3R), which migrate to the nucleus, bind to GLI-bind-
ing consensus sequences, and repress transcription of
HH target genes. For GLI2, however, it was shown that
degradation and clearance predominated over formation
H signaling pathways. In the absence of HH ligands, PTCH localizes to the
lation-dependent ubiquitination of GLI transcription factors, leading to either
I3 to form a repressive form (GLI3R) lacking C-terminal activation domains.
s transcription of HH target genes. In the presence of HH ligands (SHH, IHH,
cilium. This results in increased stability and nuclear accumulation of GLI
2, CCND1, and ABCG2, among others).nical H
osphory
is of GL
epresseof the repressor form, which is unlike GLI3 and makes
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ing.26–28 Activation of canonical HH signaling leads to
abrogation of phosphorylation-dependent proteolytic
degradation of all GLI proteins, increasing their cytoplas-
mic and nuclear levels and so also increasing transcrip-
tion of HH target genes: GLI1, PTCH1, PTCH2, BCL2,
ABCG2, CCND2, FGF4, VEGFA (previously VEGF), PAX6,
PAX7, PAX9, jagged 1 (JAG1), andMYCN, among others.
Several regulatory steps control HH pathway signal-
ing. HH-interacting protein (HIP) competes with PTCH
for HH binding and attenuates HH signaling.29 In mam-
malian cells, the suppressor of fused protein (SUFU) is
a key regulator of the HH pathway, especially at the
level of GLI. SUFU inhibits nuclear translocation of GLI
proteins by sequestering them in the cytoplasm and
thus inhibiting their transcriptional activity.30 In addi-
tion to cytoplasmic sequestration, SUFU also localizes
to the nucleus and there suppresses GLI-driven tran-
scription. Nuclear SUFU associates with GLI-binding
sites on the DNA and represses gene transcription by
recruiting the SAP18-mSin3 complex to GLI promot-
ers.31 Additional modes of regulating HH signaling in-
clude PKA-mediated phosphorylation of GLI1 on resi-
due Thr374, in the vicinity of the nuclear localization
sequence, resulting in its cytoplasmic sequestration,32
and increased stability and nuclear accumulation of
GLI1 induced by GTPase HRas and GTPase NRas via
the RAS-RAF-MEK signaling axis.33
The HH Signaling Pathway in Hematopoiesis
and Lymphopoiesis
Vertebrate hematopoiesis has two different phases: prim-
itive (embryonic) hematopoiesis and definitive (adult) he-
matopoiesis. Primitive or embryonic hematopoiesis is
characterized by the commitment of embryonic meso-
derm to hematopoietic precursors such as embryonic (or
primitive) erythrocytes and macrophages.34 The require-
ment of IHH in primitive hematopoiesis was established
by Dyer et al,35 who showed that IHH ligand secreted by
the endoderm was sufficient to induce formation of he-
matopoietic and endothelial cells. That IHH is a signal
playing a key role in the development of the earliest
hematovascular system was also supported by another
study, in which IHH-deficient embryonic stem cell lines
were unable to form blood islands and showed abnormal
vascular morphology.36
Definitive hematopoiesis is autonomously initiated with
the formation of multipotent hematopoietic stem cells in
the aorta-gonad-mesonephros region.37 In contrast to
primitive hematopoiesis, there is conflicting data regard-
ing the role of HH pathway in definitive hematopoiesis. A
study with zebrafish embryo with loss-of-function SHH
mutation showed defects in adult hematopoietic stem cell
formation.38 Several other studies have been conducted
on the function of SMO in hematopoiesis, but their con-
clusions are fairly inconsistent. Gao et al39 showed that
SMO-deficient hematopoietic stem cells were not af-
fected in terms of differentiation, self-renewal, and regen-
eration of the immune system; they also demonstratedthat SMO-deficient hematopoietic stem cells preserved
the gene expression signature specific for hematopoietic
stem cells. Similar results were observed by Hofmann et
al40 and Dierks et al.41 Zhao et al,42 however, demon-
strated that SMO-deficient mice clearly had a defect in
long-term hematopoietic stem cell function in primary and
secondary transplants and that therefore SMO is required
for hematopoietic stem cell renewal in vivo. More recently,
a Gli1null mouse study by Merchant et al43 showed de-
creased proliferation of hematopoietic stem cells and
myeloid progenitors. Gli1null mice had more long-term
hematopoietic stem cells that were more quiescent and
showed increased engraftment after transplantation. In
contrast, myeloid development was adversely affected,
with decreased in vitro colony formation, decreased in
vivo response to granulocyte colony-stimulating factor
(G-CSF), and impaired leukocyte recovery after treat-
ments with cytotoxic drugs. Results from the Merchant et
al43 study support the notion that GLI1 is a regulator of
self-renewal of hematopoietic stem cells and drives my-
eloid cell proliferation: loss of GLI1 impairs hematopoie-
sis in situations of stress and impairs the ability to recover
after cytotoxic injury or respond to stimulatory cytokines.
The thymus is the organ of T-cell development and
maturation. In the embryonic stage, progenitor cells are
seeded to the thymus from fetal liver; after birth, progen-
itor cells migrate from the bone marrow to the thymus. In
the adult, common lymphoid progenitors enter the blood
vessels in the corticomedullary junction or medulla and
undergo progressive differentiation of pre-T-cells (thymo-
cytes) as double negative (DN; CD4CD8), double pos-
itive (DP; CD4CD8), and finally single positive (SP;
either CD4CD8 or CD4CD8) mature T-cell subsets.
The DN stage is further divided into four smaller subsets,
based on the expression status of CD25 and CD44: DN1
cells are CD25CD44, DN2 cells are CD25CD44,
DN3 cells are CD25CD44, and DN4 cells are
CD25CD44.44 T-cell lineage specification and T-cell
receptor  (TCR-) rearrangement occur in the DN2 and
DN3 stages.45 Pre-TCR signaling is required for survival,
proliferation, and differentiation to the DP stage, and is
negatively regulated by SHH and IHH signaling.46–50
During transition from DP to SP, both positive and nega-
tive selections occur. This developmental program is reg-
ulated by the thymic stroma, and one way in which the
stroma signals to developing thymocytes is by produc-
tion of HH ligands.
The different components of the HH signaling path-
way have been reported to be expressed in the thymus
and to play an important role regulating the prolifera-
tion and differentiation of thymocytes. HH ligands are
produced by stromal, thymic, epithelial, and dendritic
cells.46,47,51–53 The fact that thymocytes also express HH
ligands (especially IHH in DP-stage thymocytes) was
demonstrated by Outram et al.46 PTCH and SMO are
expressed mainly by immature thymocytes. SMO shows
a peak expression at DN2, with a decrease in subse-
quent stages.47 GLI1 shows the highest expression at
DN2 and DN3, then decreases to its minimal level at DP.
GLI1 is required for normal differentiation of DN3.54 GLI2
is expressed at DN1 and DN2 at the highest level, down-
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pression of GLI3 is highest at DN1 and DN4 in fetal
thymocytes, but is not detected in adult thymocytes. GLI3
is necessary for DN to DP differentiation, especially after
pre-TCR signaling.55 HH signaling is necessary for pro-
liferation and survival of DN1 and differentiation to DN2
(early stages of thymocyte development).46,53,56 As dif-
ferentiation progresses, immature thymocytes move
away from the cortical-medullary junction (which has high
expression of HH proteins), resulting in a gradual loss of
HH stimulation. These events coincide with the induc-
tion of TCR- rearrangement. Generation of a produc-
tive TCR- rearrangement results in pre-TCR assem-
bly, surface expression, and signaling.53 HH signaling
also influences late stages of T-cell development and
T-cell activation.57–60
Sacedón et al61 reported that SHH ligand is produced
by follicular dendritic cells within germinal centers of lym-
phoid follicles, and that SHH ligand protects germinal
center B cells from apoptosis. They also showed that
germinal center B cells express the HH receptors
PTCH and SMO, and that their survival is altered after
inhibition of the HH signaling pathway. These data
indicate that HH signaling has a role in the biology of
lymphoid follicles and is involved in rescuing or pro-
tecting germinal center cells from apoptosis.
HH proteins are expressed in all lymphoid organs and
are secreted as soluble ligands by stromal cells; IHH is
secreted in bone marrow and SHH in lymph nodes and
spleen.61,62 The expression levels of HH-related proteins
(HH ligands and the transcription factors GLI1, GLI2, and
GLI3) were explored in reactive lymph nodes using im-
munohistochemistry (for HH ligands, a polyclonal anti-
body that recognizes all three HH proteins was used).63
HH ligands were detected in the cytoplasm of follicular
dendritic cells, endothelial cells, and macrophages, but
not in germinal center lymphocytes. GLI1 expression was
not seen, but GLI2 expression was detected in some
centroblasts and centrocytes surrounding follicular den-
dritic cells within germinal centers supporting the exis-
tence of an HH ligand-mediated stroma-lymphocyte in-
teraction, as shown by Sacedón et al.61 Germinal center
lymphocytes, follicular dendritic cells and endothelial
cells were negative for GLI1. Expression of GLI3 was
detected in follicular dendritic cells and endothelial cells,
but not in germinal center lymphocytes. In the thymus,
GLI3 was expressed by cortical and medullary stromal
cells (including epithelial cells, endothelial cells, and his-
tiocytes), but thymocytes were negative.64
Aberrant Activation of HH Signaling in Cancer
The initial observation of GLI1 involvement in glioma de-
velopment was the first indication of the role of HH sig-
naling in tumorigenesis.65 Later, a definitive link between
the HH pathway and cancer was established by the iden-
tification of heterozygote mutations affecting PTCH and
resulting in abnormal activation of the HH signaling path-
way in sporadic basal cell carcinomas, rhabdomyosar-
comas, and neural tumors.66 In addition, association ofHH signaling with other tumors such as pancreatic ade-
nocarcinoma and lung, gastric, prostate, and esopha-
geal cancer was also identified.67–69
In cancer, several mechanisms by which HH signaling
can be aberrantly activated have been described. The
first is through mutation of members of the HH signaling
leading to hyperactivation of the pathway (eg, PTCH1
mutations in Gorlin’s syndrome, sporadic basal cell car-
cinomas, and a significant fraction of medulloblastomas;
SUFU-inactivating mutations in medulloblastoma and
rhabdomyosarcoma; and activating mutation of SMO in
basal cell carcinomas).16,66,70–73 In these cases, HH sig-
naling activation is ligand-independent, and HH deregu-
lation is thought to be the initiating pathogenic event. The
second model displays excessive and/or inappropriate
expression of HH ligands (ligand-dependent signaling
activation), resulting in autocrine and/or paracrine stimu-
lation of cancer cells. An additional model in which the
tumor cells secrete HH ligands activating HH signaling in
the stroma has also been suggested. In this model, in
response to the tumor-secreted HH ligands, stromal cells
secrete growth factors contributing to proliferation and/or
survival of the tumor cells. This model of HH activation
has been shown in pancreatic and colorectal cancers.74
The autocrine pattern of HH activation has been de-
scribed in some epithelial cancers (breast, pancreas,
lung, prostate, and gastrointestinal tract).69,75–79 In con-
trast to cancers with mutational activation of HH signal-
ing, in the ligand-dependent model HH deregulation is
not the initiating pathogenic event but still plays a role in
the pathobiology of the tumor by contributing to tumor
maintenance and growth.
Aberrant Activation of the HH Signaling
Pathway in Hematological Malignancies
Although inappropriate activation of the HH signaling
pathway has been shown in some cancers, the contribu-
tion of the HH signaling pathway in hematological malig-
nancies has not been thoroughly examined. Emerging
data indicate that the HH pathway is active in some
hematopoietic malignancies and that this activation con-
tributes to the biology of these neoplasms. To date, he-
matopoietic malignancies have not been found to harbor
activating or inhibiting mutations in HH signaling compo-
nents, and current data suggest that in most hematopoi-
etic neoplasms HH signaling does not play an indepen-
dent role in tumor initiation but instead contributes to
tumor maintenance, growth, and resistance to chemo-
therapy. There are also data suggesting that HH signal-
ing can participate in cancer stem cell survival and/or
expansion in some malignant hematopoietic neoplasms,
such as plasma cell myeloma, chronic myelogenous leu-
kemia and acute leukemias.
The mechanisms by which HH signaling is activated
in hematological malignancies are not clear at this
time. A schematic representation of mechanisms of
activation of HH signaling in hematological cancers is
shown in Figure 2.
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ligands contributing to the activation of HH signaling in
the tumor cells has been described in low-grade B-cell
neoplasms, including chronic lymphocytic leukemia/
small lymphocytic lymphoma (CLL), an indolent form of
B-cell lymphoma, as well as in plasma cell myeloma, and
has been suggested in mantle cell lymphoma (MCL).80
An autocrine pattern has been suggested in acute my-
eloid leukemia and anaplastic lymphoma kinase (ALK)-
positive anaplastic large cell lymphoma (ALCL). Both
paracrine and autocrine patterns have been found in
diffuse large B-cell lymphoma (DLBCL).
GLI1 is located at 12q13, and gains at this locus and/or
extra copies of chromosome 12 have been reported in
B-cell lymphomas, including splenic and nodal marginal
zone lymphoma, DLBCL, and MCL.81–84 We have de-
tected a few extra copies of GLI1, DHH, or SMO genes,
caused by chromosomal aneuploidy rather than true
gene amplification, in DLBCL cell lines and in patient
samples (unpublished data), which may contribute to HH
activation but does not fully explain activation of the path-
way. Mutations of HH signaling-related genes have not
been reported, and it is not known whether specific mi-
croRNAs are involved in the activation of HH signaling in
malignant lymphomas and leukemias. It has been shown
that the microRNA-17/92 cluster synergizes with HH sig-
naling in cerebellar granule cell precursors and in
medulloblastoma.85
Recent evidence suggests that activation of HH sig-
naling in cancer in general, but also in hematological
neoplasms in particular, results at least in part from inte-
gration of multiple deregulated oncogenic signaling in-
puts in the final signaling effectors of the HH pathway, the
GLI transcription factors (see review by Stecca and Ruiz
I Altaba).86 Growth factors such as platelet-derived
growth factor, epidermal growth factor, and insulin-like
growth factor 1 increase activation of HH signaling that isdependent of the activation of PI3K-AKT pathway.87,88
Interplay among NF-B, RAS-RAF-MEK, TGF-, notch,
and HH signaling is also supported by multiple lines of
evidence.86,89 This view of the interconnectivity of numer-
ous oncogenic pathways has important implications for
understanding how the major oncogenic pathways inter-
act and also for the development of more effective and
focused anticancer therapies.
HH Signaling in B-Cell Neoplasms
Using a c-Myc-driven mouse model that generated a
wide range of B-cell malignancies including 40% slow-
growing (low-grade) plasmacytomas, Dierks et al80
showed that lymphoma cells undergo apoptosis in the
absence of their stromal microenvironment and that, to
some extent, they are protected from apoptosis in the
presence of HH ligands or SMO agonists. They also
showed that the suppression of IHH secretion by
the stromal cells using an IHH short hairpin RNA con-
struct substantially decreased lymphoma cell growth; in
the same study, similar results were obtained using hu-
man malignant lymphomas.80 These findings suggest
that HH ligands secreted by the tumor microenvironment
(stromal cells from bone marrow, lymph node, and
spleen) are survival factors for low-grade B-cell lympho-
mas and plasma cell myeloma and support a paracrine
role for HH signaling in low-grade B-cell neoplasms. This
is of interest because inhibition of HH signaling could
provide a novel strategy in these neoplasms.
Two additional studies have documented the role of
HH signaling in CLL.90,91 Hegde et al90 found that the
PTCH-SMO-GLI axis is functional in CLL cells, and that
inhibition of HH signaling by cyclopamine abrogated
bone marrow stroma-induced survival of CLL cells. These
Figure 2. Schematic diagram of mechanisms of
activation of HH signaling in hematological can-
cers. Both paracrine and autocrine activation of
HH signaling has been observed in hematolog-
ical cancers (paracrine mainly in CLL and plasma
cell myeloma, and both paracrine and autocrine
in DLBCL). An autocrine mechanism of activa-
tion has also been reported in acute myeloid
leukemia and in ALK-positive anaplastic large
cell lymphoma (ALKLALCL). Activation of
PI3K-AKT (activation of other oncogenic path-
ways not shown) contributes to the activation of
HH signaling. NPM-ALK in ALK-positive ALCL
enhances the stability and consequently the tran-
scriptional activity of GLI1 through activation of
PI3K-AKT signaling. Examples of HH inhibitors,
either natural products or synthetic compounds
are shown (red boxes). 5E1 and robotnikinin
bind and inactivate HH ligands, cyclopamine
and GDC-0499 bind and inactivate SMO, and
GANT-61 and HPI-1 interfere with GLI transcrip-
tional activity.authors also reported a correlation between expression
HH in Hematological Cancers 7
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progression and clinical outcome.90 In the other study,
Desch et al91 found that activation of HH signaling via
SMO-independent GLI1 is more relevant in CLL than the
classical PTCH-SMO-GLI axis, and that the observed
CLL sensitivity to cyclopamine (reported by Hegde et
al90) is in part due to nonspecific off-target effects.91 They
based these conclusions on observations that primary
CLL cells were highly sensitive to GLI inhibition (as de-
termined by using the GLI antagonist GANT61 or by
silencing GLI1 gene expression using shRNA) and that
silencing SMO did not influence CLL viability. Although
the two sets of findings seem discordant, both of these
studies support the functionality of HH signaling and the
possibility of targeting this pathway in CLL. Studies with
more potent and more specific SMO inhibitors than cy-
clopamine, such as vismodegib (GDC-0449), may help to
further elucidate the role of SMO in the activation of HH
signaling in this neoplasm.
More recently, HH signaling has been found to be
active and functional in DLBCL, the most frequent ag-
gressive subtype of B-cell lymphoma.92 High expression
of the HH ligand receptors SMO and PTCH, and also the
transcription factors GLI1 and GLI2, but not GLI3, have
been detected in tumor samples and in DLBCL cell
lines.63,92 Inhibition of HH signaling using the SMO inhib-
itor KAAD-cyclopamine resulted in decrease of cell num-
ber and colony formation in DLBCL cells, in particular in
those DLBCL cell lines with high expression of SMO.92
Similar results in cell viability have been obtained using
other SMO inhibitors as well as gene-silencing ap-
proaches (GLI1 and GLI2). It was shown that inhibition of
HH signaling predominantly induced cell cycle arrest in
DLBCL cell lines of germinal center type [cells carrying
the t(14;18) rearrangements] and mainly apoptosis in
those of activated B-cell type (ABC type). The resistance
to apoptosis observed in germinal center DLBCL cells
can be overcome using BCL2 functional inhibitors, sug-
gesting that the functionality and expression levels of
BCL2 are important in determining susceptibility to apop-
tosis induced by SMO inhibitors.92
Variable cytoplasmic expression levels of HH ligands
(SHH, IHH, and DHH), including expression of the HH
precursor (full length) and the N-terminal HH peptide,
have been detected in DLBCL tumors and cell
lines.63,92,93 Moreover, the secreted HH N-terminal pep-
tide was detected in culture medium collected from
DLBCL cell lines, and blocking secreted HH ligands with
the monoclonal antibody 5E1 or silencing the expression
of SHH and IHH genes by siRNA resulted in decreased
expression levels of GLI1 associated with decreased ex-
pression of its downstream target genes.92 These data
indicate that HH ligands are synthesized, processed, and
secreted by DLBCL cells and that the canonical HH li-
gand-PTCH-SMO-GLI axis is functional in DLBCL cells.
These data provide evidence of the existence of an au-
tocrine HH signaling loop in this lymphoma type. In the
same study, however, expression of HH ligands or se-
creted HH N-terminal peptide were not detected in cell
lysates or in the culture medium collected from primary
CLL cells, respectively.92 The gain of cell-autonomousactivation of the HH pathway that is seen in DLBCL cells
(in contrast to CLL cells, in which HH ligands are pro-
vided by stromal cells) likely represents a survival and/or
proliferative advantage for the lymphoma cells and is an
indication, at least to some degree, of stromal indepen-
dence.
In addition to the above-mentioned autocrine model, a
paracrine pattern of activation of HH signaling in DLBCL
has also been demonstrated.94 Coculturing DLBCL cell
lines with the human bone marrow stroma cell line HS5 in
transwell experiments (without direct contact between
DLBCL and stromal cells) resulted in activation of HH
signaling in the tumor cells, that can be blocked with
SMO inhibitors. In these experiments, it was also shown
that stroma-induced activation of HH signaling contrib-
utes to the increase of chemotolerance of DLBCL cells.
This stroma-induced chemotolerance induced by activa-
tion of HH signaling in the tumor cells was mediated by
up-regulation of the expression of antiapoptotic proteins
such as BCL2, BCL2A1, and BCL-XL, as well as by
up-regulation of the ATP binding cassette sub-family G
member 2 (ABCG2). Functional inhibition of SMO,
ABCG2, and BCL2 abrogated stroma-induced chemotol-
erance in DLBCL cells, highlighting the potential adjuvant
therapeutic value of these strategies in DLBCL and other
cancers with abnormal activation of HH signaling. In the
same study, ABCG2 was found to be a direct transcrip-
tional target of HH signaling.94
In another report, Hegde et al95 documented the role
of HH signaling in MCL, an aggressive subtype of B-cell
lymphoma, showing that PTCH, SMO, GLI1, and GLI2 are
expressed both in MCL cell lines and in primary MCL
cells. Furthermore, they also demonstrated that treatment
with exogenous HH ligands increased cell proliferation of
one of the MCL cell lines (JVM2); inhibition of HH signal-
ing in that same cell line resulted in decrease in cell
proliferation.95
Recently, expression of GLI transcription factors was
studied in classic Hodgkin’s lymphoma.64 GLI3 was
found universally expressed in Hodgkin-Reed Sternberg
cells, but was not expressed or was significantly less
frequently expressed in other lymphomas. Hodgkin-Reed
Sternberg cells express relatively low levels of other HH-
related molecules, including HH ligands and the tran-
scription factors GLI1 and GLI2. GLI3 is also expressed
by stromal cells in lymph node (including follicular den-
dritic cells, histiocytes, and endothelial cells) and in thy-
mus (histiocytes, endothelial cells, and epithelial cells),
but not by mature or immature lymphocytes.63,64 Hager-
Theodorides et al55,96 showed that GLI3 in thymic stromal
cells regulates T-cell selection and differentiation of thy-
mocytes. Whether GLI3 plays a similar regulatory role in
the modulation of the T-cell response and microenviron-
ment in classic Hodgkin’s lymphoma remains to be de-
termined.
Activation of the HH pathway has also been docu-
mented in plasma cell myeloma. As noted above, HH
ligands secreted by tumor microenvironment are survival
factors for plasma cell myeloma.80 PTCH, SMO, and GLI1
were found to be overexpressed in both human plasma
cell myeloma cell lines and primary tumor samples, com-
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al97 found that HH signaling is required for self-renewal
and maintenance of the tumor stem cell compartment
(CD138, CD19) in plasma cell myeloma. Moreover,
inhibition of HH pathway activity induced the loss of tu-
mor stem cell compartment, accompanied by the induc-
tion of plasma cell differentiation and inhibition of clono-
genic growth potential.97
HH Signaling in T-Cell Neoplasms
Dysregulated HH signaling may also be important in ma-
ture T-cell malignancies. ALK-positive ALCL is an ag-
gressive type of non-Hodgkin’s lymphoma of T-cell-null
lineage. This lymphoma is characterized by chromo-
somal aberrations that lead to constitutive activation of
ALK. The most common is translocation t(2;5)(p23;q35),
which produces a fusion between the nucleophosmin
gene (NPM1) and ALK, leading to expression of the NPM-
ALK fusion protein.98 HH ligands and GLI1 have been
found to be highly expressed in ALK-positive ALCL tu-
mors and cell lines.87 NPM-ALK, through activation of
PI3K-AKT, contributes to activation of HH signaling,
which in turn contributes to cell proliferation and survival
in ALK-positive ALCL and to the oncogenic effect of
NPM-ALK.87 An autocrine role for HH signaling in ALK-
positive ALCL has also been suggested. Extra copies of
the SHH gene, but not of GLI1, have been found In
ALK-positive ALCL tumors and cell lines.87
HH Signaling in Chronic Myelogenous
Leukemia and Acute Leukemias
Chronic myelogenous leukemia (CML) is a clonal my-
eloproliferative neoplasm characterized by the presence
of the Philadelphia chromosome [t(9;22)] resulting in the
expression of the BCR-ABL1 fusion gene. Dierks et al41
showed that HH signaling is activated in BCR-ABL1-pos-
itive leukemia stem cells through up-regulation of SMO.
Pharmacological inhibition of SMO reduced CML leuke-
mia stem cells in vivo and enhanced time to relapse. They
also showed that the development of retransplantable
BCR-ABL1-positive leukemias was abolished in the ab-
sence of SMO expression. Zhao et al42 reported similar
findings. They showed that loss of SMO causes depletion
of CML stem cells, whereas constitutive active SMO aug-
ments CML stem cell number and accelerates disease.42
Activation of HH signaling was also reported in acute
myeloid leukemias by Kobune et al,99 who showed that,
in acute myeloid leukemia cell lines, the degree of HH
activation was greater in primary CD34 blasts and in
CD34 cell lines, compared with CD34 blasts.99 HH
inhibition (achieved using cyclopamine or by using the
monoclonal antibody 5E1 to neutralize HH ligands) in-
duced apoptosis in CD34 cell lines and sensitized them
against the chemotherapeutic agent cytarabine. In that
study, cyclopamine treatments failed to affect growth or
survival of acute myeloid leukemia cell lines without SMO,
supporting the specificity of cyclopamine.99 Lin et al100reported that expression of HH signaling components isalso frequent in human B-cell acute lymphoblastic leuke-
mias, and that the level of pathway activity can be mod-
ulated by HH ligand or SMO inhibitors. They also
showed, both in vitro and in vivo, that inhibition of HH
signaling affects highly clonogenic B-cell acute lym-
phoblastic leukemia cells primarily by limiting their self-
renewal potential. Some reports have also suggested
that HH signaling promotes the growth of T-cell acute
lymphoblastic leukemia.101,102
Small-Molecule Modulators of HH Signaling
More than 50 compounds have been identified that inhibit
HH signaling. Although the mechanisms of action of
some of the HH signaling inhibitors are not fully under-
stood, these molecules target several key steps in the
process of HH activation (Figure 2). These small-mole-
cule compounds can be categorized as follows: i) HH
ligand inhibitors [HH neutralizing antibodies (5E1), and
robotnikinin]; ii) SMO antagonists (cyclopamine, the first
inhibitor discovered, and its derivatives, as well as syn-
thetic compounds such as GDC-0449, Cur61414, and
statins); iii) intraflagellar transport protein inhibitors (HH
pathway inhibitors HPI-2, HPI-3, and HPI-4); and iv) direct
or indirect GLI transcriptional inhibitors, including GLI
antagonists (GANTs). GANT61 interferes with GLI bind-
ing to the gene promoters. HPI-1 targets an unclear pri-
mary cilium-independent process such as a post-trans-
lational modification of the GLI protein and/or interaction
between GLIs with a cofactor103 and physalins (physalin
F) that indirectly antagonize GLI function.104,105
Conclusions
In summary, emerging data demonstrate abnormal acti-
vation of the HH signaling pathway in lymphoid and my-
eloid neoplasms. Despite the inability of HH signaling to
start tumorigenesis in hematological malignancies, HH
signaling has been shown to have proliferative and sur-
vival roles, contributing to maintenance of the cancer
stem-cell component and enhancing tolerance or resis-
tance to chemotherapeutic agents. For these reasons, it
will be important to further understand the biology of HH
signaling in these neoplasms, and in particular to identify
the causative factors for its aberrant activation and de-
regulation, its crosstalk with other oncogenic signaling
pathways, and how HH target genes contribute to main-
tenance of the malignant phenotype. Although HH sig-
naling pathway blockade alone might be insufficient for
the treatment of lymphomas or leukemias, the current
available data provide a rationale for using HH pathway
antagonists as adjuvant therapeutic agents to increase
susceptibility to current chemotherapeutic agents or to
potentiate other targeted therapies for hematological
neoplasms.
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